Tanzisertib

DB11798InvestigationalSmall molecule

Tanzisertib has been used in trials studying the treatment of Fibrosis, Discoid Lupus, Pulmonary Fibrosis, Interstitial Lung Disease, and Lung Diseases, Interstitial, among others.

Mechanism: Pharmacologically active on Mitogen-activated protein kinase 10, Mitogen-activated protein kinase 9, and Mitogen-activated protein kinase 8
Curator reviewed
Formula / weight: C₂₁H₂₃F₃N₆O₂ · 448.4415 g/mol (avg)
Also known as: 4-[[9-(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-trans-cyclohexanol · CYCLOHEXANOL, 4-((9-((3S)-TETRAHYDRO-3-FURANYL)-8-((2,4,6-TRIFLUOROPHENYL)AMINO)-9H-PURIN-2-YL)AMINO)-, TRANS- · TRANS-4-((9-((3S)-TETRAHYDROFURAN-3-YL)-8-((2,4,6-TRIFLUOROPHENYL)AMINO)-9H-PURIN-2- YL)AMINO)CYCLOHEXANOL
Code names: CC-930 · JNK-930

Resolves to

Compound

UNIIM5O06306UOCAS899805-25-5ChEMBLCHEMBL1950289PubChem11597537

Structure

InChIKeyIBGLGMOPHJQDJB-IHRRRGAJSA-NSMILES[H][C@@]1(CCOC1)N1C(NC2=C(F)C=C(F)C=C2F)=NC2=CN=C(N[C@@]3([H])CC[C@]([H])(O)CC3)N=C12

Targets

P53779MAPK10P45984MAPK9P45983MAPK8

What you can answer from here — as of June 15, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tanzisertib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account